Resistance Wars: Master Clinicians Discuss Emerging Strategies for Fighting Infection CME

Philip S. Barie, MD, MBA, FCCM, FACS; Marin H. Kollef, MD, FACP, FCCP Author Information and Disclosures

Release Date: January 31, 2008; Valid for credit through January 31, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Estimated time to complete the educational activity 1 hour.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 SynerMed® Communications
Ortho McNeil Janssen
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the prevalence, risk factors, and potential consequences of serious bacterial infections;
  2. List the pathogens of significance found in nosocomial, community-acquired, and healthcare-associated infections;
  3. Recognize treatment challenges for serious bacterial infections due to increasing trends of antibiotic resistance;
  4. Implement management and pharmacologic strategies for the effective treatment of serious resistant bacterial infections in an era of resistance.
Authors and Disclosures

Philip S. Barie, MD, MBA, FCCM, FACS
Disclosure: Philip S. Barie, MD, MBA, is a consultant/advisor for AstraZeneca, Inc.; Cadence Pharmaceuticals; Eli Lilly and Co., Inc.; Merck & Co., Inc.; NovaBay Pharmaceuticals, Inc.; Ortho-Biotech; Ortho-McNeil Laboratories; Schering-Plough, Inc.; and Wyeth Laboratories. He is on the Speaker's Bureau for Eli Lilly and Co., Inc.; Merck and Co., Inc.; and Wyeth Laboratories.


Marin H. Kollef, MD, FACP, FCCP
Disclosure: Marin H. Kollef, MD, is a consultant/advisor and a member of the speaker's bureau for Elan; Johnson & Johnson; Merck & Co., Inc.; and Pfizer, Inc.


 
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Penn State College of Medicine and SynerMed® Communications. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.